CUE
Price
$0.80
Change
+$0.01 (+1.27%)
Updated
Oct 17 closing price
Capitalization
61.18M
18 days until earnings call
GRI
Price
$1.94
Change
-$0.01 (-0.51%)
Updated
Oct 17 closing price
Capitalization
4.88M
Interact to see
Advertisement

CUE vs GRI

Header iconCUE vs GRI Comparison
Open Charts CUE vs GRIBanner chart's image
Cue Biopharma
Price$0.80
Change+$0.01 (+1.27%)
Volume$96.92K
Capitalization61.18M
GRI Bio
Price$1.94
Change-$0.01 (-0.51%)
Volume$149.31K
Capitalization4.88M
CUE vs GRI Comparison Chart in %
CUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GRI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CUE vs. GRI commentary
Oct 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CUE is a Hold and GRI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 19, 2025
Stock price -- (CUE: $0.80 vs. GRI: $1.94)
Brand notoriety: CUE and GRI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CUE: 50% vs. GRI: 10%
Market capitalization -- CUE: $61.18M vs. GRI: $4.88M
CUE [@Biotechnology] is valued at $61.18M. GRI’s [@Biotechnology] market capitalization is $4.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CUE’s FA Score shows that 1 FA rating(s) are green whileGRI’s FA Score has 2 green FA rating(s).

  • CUE’s FA Score: 1 green, 4 red.
  • GRI’s FA Score: 2 green, 3 red.
According to our system of comparison, GRI is a better buy in the long-term than CUE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CUE’s TA Score shows that 6 TA indicator(s) are bullish while GRI’s TA Score has 6 bullish TA indicator(s).

  • CUE’s TA Score: 6 bullish, 4 bearish.
  • GRI’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both CUE and GRI are a good buy in the short-term.

Price Growth

CUE (@Biotechnology) experienced а +0.09% price change this week, while GRI (@Biotechnology) price change was +4.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

CUE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CUE($61.2M) has a higher market cap than GRI($4.88M). CUE YTD gains are higher at: -26.954 vs. GRI (-86.224). GRI has higher annual earnings (EBITDA): -10.03M vs. CUE (-36.07M). CUE has more cash in the bank: 27.5M vs. GRI (5.12M). GRI has less debt than CUE: GRI (96K) vs CUE (7.63M). CUE has higher revenues than GRI: CUE (8.29M) vs GRI (0).
CUEGRICUE / GRI
Capitalization61.2M4.88M1,254%
EBITDA-36.07M-10.03M360%
Gain YTD-26.954-86.22431%
P/E RatioN/A0.02-
Revenue8.29M0-
Total Cash27.5M5.12M537%
Total Debt7.63M96K7,952%
FUNDAMENTALS RATINGS
CUE vs GRI: Fundamental Ratings
CUE
GRI
OUTLOOK RATING
1..100
2183
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
1
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6059
P/E GROWTH RATING
1..100
10016
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GRI's Valuation (1) in the null industry is in the same range as CUE (30) in the Biotechnology industry. This means that GRI’s stock grew similarly to CUE’s over the last 12 months.

GRI's Profit vs Risk Rating (100) in the null industry is in the same range as CUE (100) in the Biotechnology industry. This means that GRI’s stock grew similarly to CUE’s over the last 12 months.

GRI's SMR Rating (100) in the null industry is in the same range as CUE (100) in the Biotechnology industry. This means that GRI’s stock grew similarly to CUE’s over the last 12 months.

GRI's Price Growth Rating (59) in the null industry is in the same range as CUE (60) in the Biotechnology industry. This means that GRI’s stock grew similarly to CUE’s over the last 12 months.

GRI's P/E Growth Rating (16) in the null industry is significantly better than the same rating for CUE (100) in the Biotechnology industry. This means that GRI’s stock grew significantly faster than CUE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CUEGRI
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 5 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 4 days ago
89%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 6 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
CUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GRI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PDEX26.222.31
+9.68%
Pro-Dex
MGA44.770.02
+0.04%
Magna International
TSAT32.16-0.28
-0.88%
Telesat Corp
SEDG37.02-3.09
-7.70%
SolarEdge Technologies
NDRA6.13-0.87
-12.43%
ENDRA Life Sciences Inc

CUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, CUE has been loosely correlated with SGMT. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if CUE jumps, then SGMT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CUE
1D Price
Change %
CUE100%
+0.77%
SGMT - CUE
41%
Loosely correlated
-2.52%
INAB - CUE
40%
Loosely correlated
-1.90%
OCS - CUE
39%
Loosely correlated
+0.93%
VCYT - CUE
36%
Loosely correlated
+0.06%
GRI - CUE
36%
Loosely correlated
-0.51%
More

GRI and

Correlation & Price change

A.I.dvisor indicates that over the last year, GRI has been loosely correlated with INAB. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if GRI jumps, then INAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRI
1D Price
Change %
GRI100%
-0.51%
INAB - GRI
42%
Loosely correlated
-1.90%
NLSP - GRI
38%
Loosely correlated
+1.23%
SNSE - GRI
37%
Loosely correlated
-33.43%
GOVX - GRI
37%
Loosely correlated
-1.71%
HOWL - GRI
33%
Loosely correlated
-4.19%
More